Frenova works closely with the world’s leading minds in nephrology, chronic disease care, business and clinical research.

 

maddux

Franklin W. Maddux, MD, FACP

Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs, Fresenius Medical Care North America (FMCNA)

Dr. Franklin W. Maddux joined FMCNA in 2009 after Fresenius Medical Care acquired a company he founded, Health IT Services Group, a leading-edge electronic health record software company. Dr. Maddux has more than 30 years of health care experience, including the practice of nephrology at the Danville (Virginia) Urologic Clinic, where he served as president from 1995 to 2005.

Dr. Maddux is a clinical associate professor of medicine at the University of North Carolina School of Medicine and has served on numerous boards and regional committees involved in technology initiatives, banking and health care. He received a bachelor’s degree with high honors in mathematics from Vanderbilt University and a medical degree from the University of North Carolina at Chapel Hill, where he completed his internship, residency, chief residency and nephrology fellowship.

Additional positions and activities:

  • Founder and current board member of SpecialtyCare, a leading provider of perfusion and surgical support
  • Founder and chairman of Gamewood Technology Group, Inc., an information technology service provider in Danville, VA
  • Former president Danville Urologic Clinic
  • Volunteer physician (nephrology consultation) at the Danville Free Clinic from 2000 to 2009
th thadhani

Ravi Thadhani, MD, MPH

Professor of Medicine, Harvard Medical School; Chief of the Renal Unit, Director of Clinical Research in Nephrology, Massachusetts General Hospital

Dr. Ravi Thadhani is chief of the renal unit at the Massachusetts General Hospital, where he has worked since 1991, also serving as director of clinical research in nephrology for more than a decade. He is also professor of medicine at Harvard Medical School. In the dialysis arena, Dr. Thadhani has conducted studies examining the effect of vitamin D in the survival of chronic hemodialysis patients, and through a series of worldwide studies, links between the vitamin and dialysis survival were confirmed by more than a dozen independent investigators. Clinical practices have implemented practice patterns aligned with this work, and international practice guidelines have highlighted the series of studies Dr. Thadhani led.

Focused on the cardiovascular import of vitamin D signaling, Dr. Thadhani pursued animal models of heart disease and studied the effect of the vitamin on preventing cardiac hypertrophy. His team’s human and animal studies led to investigator-initiated multicenter, multinational clinical trials with patients affected by kidney disease. His team conducted the first randomized trial in nephrology to test the effects of active vitamin D therapy on cardiac hypertrophy. Subsequent work led to the start of another first-of-its-kind randomized trial in chronic hemodialysis subjects to test the altered immune response derived from doses of nutritional vitamin D.

A member of many prestigious groups and societies, Dr. Thadhani has published more than 150 manuscripts and authored more than 35 publications, many of which have been featured in prominent health and research journals. He earned his medical degree from the Perelman School of Medicine at the University of Pennsylvania, his master’s in public health from Harvard School of Public Health and a bachelor’s from the University of Notre Dame.

Additional positions and activities:

  • Director for Harvard Medical School's core medicine rotation at Massachusetts General Hospital
  • Associate director of research, Partners Healthcare
  • Senior scientist, Department of Obstetrics, Massachusetts General Hospital
  • Research scientist, Beth Israel Deaconess Medical Center
  • Assistant director of the Pasteur Program at Harvard Medical School
  • Assistant director of the Massachusetts Institute of Technology Clinical Research Center
  • Member of the clinical advisory board at DxNow
  • Member of scientific advisory board at Altair Nanotechnologies Inc.
  • Vice chair of the National Kidney Foundation’s clinical research committee and active member of the American Society of Nephrology
  • Ad-hoc reviewer for the New England Journal of Medicine, Journal of the American Society of Nephrology, Kidney International, American Journal of Kidney Diseases, Clinical Journal of the American Society of Nephrology, Nephrology Dialysis Transplantation, Journal of Clinical Endocrinology and Metabolism and more
  • Current editorial board member for Nephrology Dialysis and Transplantation, and former editorial board member for the Journal of the American Society of Nephrology, the American Journal of Kidney Diseases, Kidney International and the Clinical Journal of the American Society of Nephrology
chertow

Glenn Matthew Chertow, MD, MPH

Professor of Medicine and Chief, Division of Nephrology, Stanford University School of Medicine

Dr. Glenn Chertow is the Norman S. Coplon Satellite Healthcare professor of medicine and chief of the Division of Nephrology at Stanford University School of Medicine. He completed his undergraduate education at University of Pennsylvania and medical education at Harvard, as well as his residency in internal medicine and fellowship in nephrology at Brigham and Women’s Hospital before joining the Harvard faculty, where he remained until 1998. Dr. Chertow then joined the faculty at University of California San Francisco (UCSF), where he served as director of clinical services in the Division of Nephrology and was promoted through the academic ranks to full professor in the Departments of Medicine and Epidemiology and Biostatistics where he remained until joining the Stanford faculty in 2007.

In addition to an active clinical practice, administrative responsibilities, teaching and mentoring, Dr. Chertow has developed and maintained a robust clinical research program. He has served or is currently serving in leadership roles for multiple NIDDK-, NHLBI- and VA-sponsored clinical trials, including HEMO, DAC, ATN, FHN, SPRINT, PRESERVE, ISCHEMIA, CURE-GN and TiME, and for several industry-sponsored clinical trials including TREAT, EVOLVE, BEACON and SYMPLICITY. He has served in an advisory capacity to the Medicare Payment Advisory Committee and National Quality Forum on issues related to the ESRD program, on NIH study sections and in multiple roles with the American Society of Nephrology, including the Public Policy Board and as JASN associate editor. Dr. Chertow’s extensive authorship, co-authorship, editorship and publication record includes:

  • Co-editor of Brenner and Rector's The Kidney, 9th Edition
  • 325+ original reports and 40+ editorials
  • Four books and 30+ textbook chapters
  • 80+ reviews as editor and in other publications
  • Present or past board member for eight organizations
  • Editor and/or board member for major kidney publications/organizations, including the American Journal of Kidney Diseases and the Journal of the American Society of Nephrology
  • Ad-hoc reviewer for more than 35 journals, including the New England Journal of Medicine, Journal of the American Medical Association, Science, Lancet, the American Journal of Medicine and every major nephrology publication

Dr. Chertow was honored by the American Kidney Fund in 2007 with the National Torchbearer Award and in 2011 with the Nephrologist of the Year Award in recognition of his contributions to the care of persons with kidney disease. He was elected to the American Society of Clinical Investigation in 2004; and, in 2015, received the Belding H. Scribner Award from ASN and was elected to the Association of American Physicians and the National Academy of Medicine.

Arnold Silva

Arnold Silva, MD, PhD

Founding Physician Partner and Director of Clinical Research, Boise Kidney & Hypertension Institute

Dr. Arnold Silva is founding physician partner and director of clinical research at Boise Kidney & Hypertension Institute, in partnership with Frenova Renal Research. Dr. Silva received his bachelor’s and master’s degrees in biology from California State University in Fresno. He received his Ph.D. from the University of Arizona in Tucson, studying the physiology of membrane transport and cell volume regulation. He received his medical degree from the University of Arizona, followed with residency training in internal medicine and a nephrology fellowship at University of Arizona affiliated hospitals.


Twice awarded for excellence in teaching at the University of Arizona, Dr. Silva served as a clinical assistant professor of medicine and also taught in many areas of biology, biochemistry and physiology for California State University and the University of California.

With over 30 years of experience in both basic science and clinical research, Dr. Silva has focused the past decade on bringing nephrology clinical trials to southern Idaho to benefit patients with kidney disease. Current and recent clinical trials include anemia in chronic kidney disease and end stage renal disease, secondary hyperparathyroidism and hyperphosphatemia, diabetic nephropathy and adult polycystic kidney disease.